162 related articles for article (PubMed ID: 33813397)
1. Lowering and Stabilizing PSA Levels in Advanced-prostate Cancer Patients With Oral Methioninase.
Han Q; Hoffman RM
Anticancer Res; 2021 Apr; 41(4):1921-1926. PubMed ID: 33813397
[TBL] [Abstract][Full Text] [Related]
2. Oral dosing of Recombinant Methioninase Is Associated With a 70% Drop in PSA in a Patient With Bone-metastatic Prostate Cancer and 50% Reduction in Circulating Methionine in a High-stage Ovarian Cancer Patient.
Han Q; Tan Y; Hoffman RM
Anticancer Res; 2020 May; 40(5):2813-2819. PubMed ID: 32366428
[TBL] [Abstract][Full Text] [Related]
3. Chronic Treatment of an Advanced Prostate-cancer Patient With Oral Methioninase Resulted in Long-term Stabilization of Rapidly Rising PSA Levels.
Han Q; Hoffman RM
In Vivo; 2021; 35(4):2171-2176. PubMed ID: 34182494
[TBL] [Abstract][Full Text] [Related]
4. Targeting methionine with oral recombinant methioninase (o-rMETase) arrests a patient-derived orthotopic xenograft (PDOX) model of BRAF-V600E mutant melanoma: implications for chronic clinical cancer therapy and prevention.
Kawaguchi K; Han Q; Li S; Tan Y; Igarashi K; Kiyuna T; Miyake K; Miyake M; Chmielowski B; Nelson SD; Russell TA; Dry SM; Li Y; Singh AS; Eckardt MA; Unno M; Eilber FC; Hoffman RM
Cell Cycle; 2018; 17(3):356-361. PubMed ID: 29187018
[TBL] [Abstract][Full Text] [Related]
5. Oral-recombinant Methioninase Converts an Osteosarcoma from Methotrexate-resistant to -sensitive in a Patient-derived Orthotopic-xenograft (PDOX) Mouse Model.
Aoki Y; Tome Y; Han Q; Yamamoto J; Hamada K; Masaki N; Kubota Y; Bouvet M; Nishida K; Hoffman RM
Anticancer Res; 2022 Feb; 42(2):731-737. PubMed ID: 35093871
[TBL] [Abstract][Full Text] [Related]
6. Recombinant methioninase effectively targets a Ewing's sarcoma in a patient-derived orthotopic xenograft (PDOX) nude-mouse model.
Murakami T; Li S; Han Q; Tan Y; Kiyuna T; Igarashi K; Kawaguchi K; Hwang HK; Miyake K; Singh AS; Nelson SD; Dry SM; Li Y; Hiroshima Y; Lwin TM; DeLong JC; Chishima T; Tanaka K; Bouvet M; Endo I; Eilber FC; Hoffman RM
Oncotarget; 2017 May; 8(22):35630-35638. PubMed ID: 28404944
[TBL] [Abstract][Full Text] [Related]
7. Oral Recombinant Methioninase Combined with Caffeine and Doxorubicin Induced Regression of a Doxorubicin-resistant Synovial Sarcoma in a PDOX Mouse Model.
Higuchi T; Kawaguchi K; Miyake K; Han Q; Tan Y; Oshiro H; Sugisawa N; Zhang Z; Razmjooei S; Yamamoto N; Hayashi K; Kimura H; Miwa S; Igarashi K; Chawla SP; Singh AS; Eilber FC; Singh SR; Tsuchiya H; Hoffman RM
Anticancer Res; 2018 Oct; 38(10):5639-5644. PubMed ID: 30275182
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of Recombinant Methioninase (rMETase) on Recalcitrant Cancer Patient-Derived Orthotopic Xenograft (PDOX) Mouse Models: A Review.
Kawaguchi K; Han Q; Li S; Tan Y; Igarashi K; Murakami T; Unno M; Hoffman RM
Cells; 2019 May; 8(5):. PubMed ID: 31052611
[TBL] [Abstract][Full Text] [Related]
9. Oral-recombinant Methioninase Converts an Osteosarcoma from Docetaxel-resistant to -Sensitive in a Clinically-relevant Patient-derived Orthotopic-xenograft (PDOX) Mouse Model.
Aoki Y; Tome Y; Wu NF; Yamamoto J; Hamada K; Han Q; Bouvet M; Nishida K; Hoffman RM
Anticancer Res; 2021 Apr; 41(4):1745-1751. PubMed ID: 33813378
[TBL] [Abstract][Full Text] [Related]
10. Afterword: Oral Methioninase-Answer to Cancer and Fountain of Youth?
Hoffman RM; Han Q; Kawaguchi K; Li S; Tan Y
Methods Mol Biol; 2019; 1866():311-322. PubMed ID: 30725426
[TBL] [Abstract][Full Text] [Related]
11. Oral-recombinant Methioninase in Combination With Rapamycin Eradicates Osteosarcoma of the Breast in a Patient-derived Orthotopic Xenograft Mouse Model.
Masaki N; Han Q; Samonte C; Wu NF; Hozumi C; Wu J; Obara K; Kubota Y; Aoki Y; Bouvet M; Hoffman RM
Anticancer Res; 2022 Nov; 42(11):5217-5222. PubMed ID: 36288875
[TBL] [Abstract][Full Text] [Related]
12. Combination of oral recombinant methioninase and decitabine arrests a chemotherapy-resistant undifferentiated soft-tissue sarcoma patient-derived orthotopic xenograft mouse model.
Higuchi T; Han Q; Miyake K; Oshiro H; Sugisawa N; Tan Y; Yamamoto N; Hayashi K; Kimura H; Miwa S; Igarashi K; Bouvet M; Singh SR; Tsuchiya H; Hoffman RM
Biochem Biophys Res Commun; 2020 Feb; 523(1):135-139. PubMed ID: 31839218
[TBL] [Abstract][Full Text] [Related]
13. Oral recombinant methioninase increases TRAIL receptor-2 expression to regress pancreatic cancer in combination with agonist tigatuzumab in an orthotopic mouse model.
Yamamoto J; Miyake K; Han Q; Tan Y; Inubushi S; Sugisawa N; Higuchi T; Tashiro Y; Nishino H; Homma Y; Matsuyama R; Chawla SP; Bouvet M; Singh SR; Endo I; Hoffman RM
Cancer Lett; 2020 Nov; 492():174-184. PubMed ID: 32739322
[TBL] [Abstract][Full Text] [Related]
14. Oral recombinant methioninase (o-rMETase) is superior to injectable rMETase and overcomes acquired gemcitabine resistance in pancreatic cancer.
Kawaguchi K; Miyake K; Han Q; Li S; Tan Y; Igarashi K; Kiyuna T; Miyake M; Higuchi T; Oshiro H; Zhang Z; Razmjooei S; Wangsiricharoen S; Bouvet M; Singh SR; Unno M; Hoffman RM
Cancer Lett; 2018 Sep; 432():251-259. PubMed ID: 29928962
[TBL] [Abstract][Full Text] [Related]
15. Recombinant methioninase infusion reduces the biochemical endpoint of serum methionine with minimal toxicity in high-stage cancer patients.
Tan Y; Zavala J; Han Q; Xu M; Sun X; Tan X; Tan X; Magana R; Geller J; Hoffman RM
Anticancer Res; 1997; 17(5B):3857-60. PubMed ID: 9427792
[TBL] [Abstract][Full Text] [Related]
16. Combination therapy of tumor-targeting Salmonella typhimurium A1-R and oral recombinant methioninase regresses a BRAF-V600E-negative melanoma.
Kawaguchi K; Higuchi T; Li S; Han Q; Tan Y; Igarashi K; Zhao M; Miyake K; Kiyuna T; Miyake M; Ohshiro H; Sugisawa N; Zhang Z; Razmjooei S; Wangsiricharoen S; Chmielowski B; Nelson SD; Russell TA; Dry SM; Li Y; Eckardt MA; Singh AS; Singh SR; Eilber FC; Unno M; Hoffman RM
Biochem Biophys Res Commun; 2018 Sep; 503(4):3086-3092. PubMed ID: 30166061
[TBL] [Abstract][Full Text] [Related]
17. Oral recombinant methioninase combined with paclitaxel arrests recalcitrant ovarian clear cell carcinoma growth in a patient-derived orthotopic xenograft (PDOX) nude-mouse model.
Sugisawa N; Higuchi T; Han Q; Hozumi C; Yamamoto J; Tashiro Y; Nishino H; Kawaguchi K; Bouvet M; Murata T; Unno M; Hoffman RM
Cancer Chemother Pharmacol; 2021 Jul; 88(1):61-67. PubMed ID: 33768300
[TBL] [Abstract][Full Text] [Related]
18. Combining Tumor-Selective Bacterial Therapy with Salmonella typhimurium A1-R and Cancer Metabolism Targeting with Oral Recombinant Methioninase Regressed an Ewing's Sarcoma in a Patient-Derived Orthotopic Xenograft Model.
Miyake K; Kiyuna T; Li S; Han Q; Tan Y; Zhao M; Oshiro H; Kawaguchi K; Higuchi T; Zhang Z; Razmjooei S; Barangi M; Wangsiricharoen S; Murakami T; Singh AS; Li Y; Nelson SD; Eilber FC; Bouvet M; Hiroshima Y; Chishima T; Matsuyama R; Singh SR; Endo I; Hoffman RM
Chemotherapy; 2018; 63(5):278-283. PubMed ID: 30673664
[TBL] [Abstract][Full Text] [Related]
19. Oral-recombinant Methioninase Lowers the Effective Dose and Eliminates Toxicity of Cisplatinum for Primary Osteosarcoma of the Mammary Gland in a Patient-derived Orthotopic Xenograft Mouse Model.
Masaki N; Han Q; Wu NF; Samonte C; Wu J; Hozumi C; Obara K; Kubota Y; Aoki Y; Miyazaki J; Hoffman RM
In Vivo; 2022; 36(6):2598-2603. PubMed ID: 36309364
[TBL] [Abstract][Full Text] [Related]
20. Extensive Shrinkage and Long-term Stable Disease in a Teenage Female Patient With High-grade Glioma Treated With Temozolomide and Radiation in Combination With Oral Recombinant Methioninase and a Low-methionine Diet.
Sato M; Han Q; Mizuta K; Mori R; Kang BM; Morinaga S; Kobayashi N; Ichikawa Y; Nakajima A; Hoffman RM
In Vivo; 2024; 38(3):1459-1464. PubMed ID: 38688589
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
